{
  "authors": [
    {
      "author": "Ning Jia"
    },
    {
      "author": "Fionnuala C Cormack"
    },
    {
      "author": "Bin Xie"
    },
    {
      "author": "Zita Shiue"
    },
    {
      "author": "Behzad Najafian"
    },
    {
      "author": "Julie R Gralow"
    }
  ],
  "doi": "10.1186/s12885-015-1536-y",
  "publication_date": "2015-07-23",
  "id": "EN115222",
  "url": "https://pubmed.ncbi.nlm.nih.gov/26197890",
  "source": "BMC cancer",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "We describe a breast cancer patient who developed heavy proteinuria (protein/creatinine ratio 9.1) and nephrotic syndrome following treatment with oral ibandronate for 29 months. CFSGS was proven by biopsy. There was no improvement 1 month after ibandronate was discontinued. Prednisone and tacrolimus were started and she experienced a decreased in proteinuria."
}